IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by APG Asset Management US Inc.

APG Asset Management US Inc. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 52,577 shares of the company’s stock after purchasing an additional 5,139 shares during the quarter. APG Asset Management US Inc. owned 0.06% of IDEXX Laboratories worth $25,048,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Riverview Trust Co bought a new stake in IDEXX Laboratories in the first quarter worth about $26,000. Crewe Advisors LLC acquired a new stake in IDEXX Laboratories during the first quarter valued at approximately $26,000. Ridgewood Investments LLC bought a new stake in IDEXX Laboratories during the second quarter worth approximately $27,000. Institutional & Family Asset Management LLC bought a new stake in IDEXX Laboratories during the second quarter worth approximately $28,000. Finally, nVerses Capital LLC acquired a new position in IDEXX Laboratories in the second quarter worth approximately $49,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on IDXX. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective for the company. Finally, Piper Sandler cut their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Trading Down 1.7 %

Shares of NASDAQ:IDXX opened at $497.76 on Thursday. The firm has a fifty day moving average of $484.48 and a two-hundred day moving average of $497.97. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The firm has a market capitalization of $41.11 billion, a P/E ratio of 48.19, a price-to-earnings-growth ratio of 4.32 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the business posted $2.67 EPS. IDEXX Laboratories’s revenue for the quarter was up 6.4% on a year-over-year basis. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.